Cyclooct-4-en-1-yl hydrogen carbonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Cyclooct-4-en-1-yl hydrogen carbonate
• 英文别名: cyclooct-4-en-1-yl hydrogen carbonate
• 化学式: C₉H₁₄O₃
• 分子量: 170.21
• InChiKey: MUSURGBOQVAHIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDES
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20150359913A1

  公开（公告）日：2015-12-17

  This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes.

  这项发明涉及用于医疗治疗和分析的标记肽构建领域。该发明涉及合成标记肽组合物、合成方法以及用于医疗治疗、成像和研究目的的合成标记肽组合物的使用方法。
• [EN] RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE<br/>[FR] RADIOLIGANDS POUR L'IMAGERIE TEP PRÉCIBLÉE ET MÉTHODES POUR LEUR UTILISATION THÉRAPEUTIQUE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2016182804A1

  公开（公告）日：2016-11-17

  Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

  本文描述了使用Al[18F]-NOTA标记的四氮唑放射配体进行Tz/TCO基于预靶向策略。与其他成像策略相比，这种成像策略使得癌症在较早的时间点能够被清晰地描绘出来，并且与直接标记抗体相比，进一步降低了对健康组织的辐射剂量。基于Al的小分子18F成像，如四氮唑，以前尚未实现，因为在放射氟化过程中四氮唑会分解。相比其他放射标记方法，放射氟化具有优势，因为除了半衰期较短外，18F更容易获得并因此更容易融入医院工作流程中。
• Radioligands for pretargeted pet imaging and methods of their therapeutic use
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US11135320B2

  公开（公告）日：2021-10-05

  Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

  本文描述的是使用 Al[18F]-NOTA 标记的四嗪放射性配体的基于 Tz/TCO 的预靶向策略。与其他成像策略相比，这种成像策略能在更早的时间点对癌症进行分界，与直接标记的抗体相比，还能进一步降低对健康组织的辐射剂量。由于四嗪在放射性氟化过程中会分解，以前还没有实现过小分子（如四嗪）的铝基 18F 成像。与其他放射性标记方法相比，放射性氟化法的优势在于，除了半衰期较短之外，18F 更容易生产，因此可纳入医院工作流程。
• RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20160331852A1

  公开（公告）日：2016-11-17

  Described herein are Tz/TCO-based pretargeting strategies using an Al[ 18 F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18 F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18 F is more readily available to produce and therefore integrated into hospital workflows.
• [EN] TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDES<br/>[FR] TÉTRAZINES/TRANS-CYCLOOCTÈNES DANS LA SYNTHÈSE EN PHASE SOLIDE DE PEPTIDES MARQUÉS
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2014117001A1

  公开（公告）日：2014-07-31

  This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes.